Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
about
Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.Fluorescent sensors for measuring metal ions in living systemsMechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.Nature of nontransferrin-bound iron.The chelatable iron pool in living cells: a methodically defined quantity.Pharmacotherapy of iron overload in thalassaemic patients.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.The role of endocytic pathways in cellular uptake of plasma non-transferrin ironNon transferrin bound iron: nature, manifestations and analytical approaches for estimationSecond international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.Pathophysiology and Clinical Manifestations of the β-Thalassemias.Clinical iron deficiency disturbs normal human responses to hypoxia.Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay.Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity.Siderophore-based detection of Fe(III) and microbial pathogens.Labile iron in cells and body fluids: physiology, pathology, and pharmacology.Human activated macrophages and hypoxia: a comprehensive review of the literature.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.Cardiac complications in beta-thalassemia: From mice to men.Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.Siderophores as molecular tools in medical and environmental applications.A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry.Pharmacological therapeutics in Friedreich ataxia: the present state.Safety profiles of Fe2+ and Fe3+ oral preparations in the treatment of iron deficiency anemia in children.Automated assay for non-transferrin-bound iron in serum samples.Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients.Ability to determine the desferrioxamine-chelatable iron fractions of nontransferrin-bound iron using HPLC.Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.The role of anaemia in oxidative and genotoxic damage in transfused β-thalassaemic patients.Hyperferritinemia after adult allogeneic hematopoietic cell transplantation: quantification of iron burden by determining non-transferrin-bound iron.Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload.Iron overload in myelodysplastic syndromes.
P2860
Q33555894-957C082D-8F3C-4A16-9416-5EF6439E6E16Q33701891-E35926C4-767F-49CD-A6EB-744A4C63BDDDQ33896372-4256ABB9-FBEC-4E3C-B782-9F92DE542085Q34083003-A02215DA-A080-4767-8965-A42E8141AF11Q34557036-137CD5CE-DE05-46AC-8665-8813961B24F3Q34658929-707758C2-D8C3-44AB-8AE1-437452678986Q35548173-0F3DEE33-8B3B-4F80-A00B-8185672F85F2Q35683841-C237DE1D-9618-4392-8B78-C51C3C577DCBQ35930563-C87A01C7-C6C6-460F-A83E-1BF3775EAF4FQ36336362-7A0C3EC8-8F72-4234-A65F-0E6B6AFFAC5EQ36420736-F58119EE-DAE4-42A0-AA0D-FE2D2C9AEEBAQ36526536-B9FC65B6-93E0-48B9-BD2A-C6F166A27325Q36951774-49E0E1AD-0107-404A-B89D-239A7E8CD577Q37416334-A42745AD-53B8-46FC-8DEC-435F06F90E56Q37429815-91829DD7-9273-47BC-9626-C1AEAC543CE6Q38031391-498FD0F3-E7D0-4DF8-A2BA-EB6E5C954EABQ38198634-F1B799D9-963D-468D-B828-7A0F90742614Q38359794-6B2521A4-D755-4437-A513-3DCD05ED77BCQ38540491-3816640B-DA90-411B-84B5-3ADD255D8FC4Q38627193-2A04DA13-6A86-4AA1-A9A6-C50C06953F4CQ38649814-54A05713-F486-4064-9257-85185755EE5FQ38686059-13A84F83-0FD9-4BAE-B5CB-EBE936C8F994Q38761669-E8C52CCE-1B58-4EC3-8FB3-2E3EBC624F07Q38855966-E97D1B40-DDD7-400B-98A2-05EF6658D089Q38919129-5CBBEC7C-B9B9-44F8-AC39-E54699642BA0Q39198457-CACDEBAF-6902-4BB6-B858-A0154FAB28B4Q39445743-04C17B06-F79E-4E11-B555-451F2AF76563Q42463346-A6EE27BD-6CA4-4EAB-801A-6DA3BEEC46C0Q42939592-1CB7B24F-FC78-4D8E-BD25-6CDDFD6AF055Q43180472-A01E68F3-E287-4E2E-80C6-5B78DC9C603AQ43910634-4460B929-83C9-4D9F-B799-81135AB67AE3Q44060767-BEFA770B-4ED1-4F0B-BA4F-854F91A6D0DDQ44386874-AC146027-A3C5-49E6-A26C-AEDDD93199FFQ46292210-280D9445-60C8-44B8-A2C4-79B9D58108B4Q46466632-ED910A40-EEF7-4952-A248-58E4D99C12C6Q50498421-2B997F3F-3CC3-4591-A512-7DA22A3ABE77Q50725581-EE2B4357-F63A-4700-AD0C-4CC9C695C6E6Q54725193-62600A9F-7285-4FD6-88AD-13C82EE966F8
P2860
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@ast
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@en
type
label
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@ast
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@en
prefLabel
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@ast
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@en
P2093
P356
P1433
P1476
Desferrioxamine-chelatable iro ...... r assessing chelation therapy.
@en
P2093
M J Ermers
P Pootrakul
Z I Cabantchik
P304
P356
10.1182/BLOOD.V97.3.792
P407
P577
2001-02-01T00:00:00Z